Literature DB >> 24793103

A review of the surgical management of sacral chordoma.

B Kayani1, S A Hanna1, M D Sewell2, A Saifuddin1, S Molloy1, T W R Briggs1.   

Abstract

BACKGROUND: Sacral chordomas are rare low-to-intermediate grade malignant tumours, which arise from remnants of the embryonic notochord. This review explores prognostic factors in the management of sacral chordomas and provides guidance on the optimal treatment regimens based on the current literature. PATIENTS AND METHODS: Electronic searches were performed using MEDLINE, Embase and the Cochrane library to identify studies on prognostic factors in the management of sacral chordomas published between January 1970 and December 2013. The literature search and review process identified 100 articles that were included in the review article. This included both surgical and non-surgical studies on the management of sacral chordomas.
RESULTS: Sacrectomy with wide resection margins forms the mainstay of treatment but is associated with high risk of disease recurrence and reduced long-term survival. Adequate resection margins may require sacrifice of adjacent nerve roots, musculature and ligaments leading to functional compromise and mechanical instability. Large tumour size (greater than 5-10 cm in diameter), dedifferentiation and greater cephalad tumour extension are associated with increased risk of disease recurrence and reduced survival. Chordomas are poorly responsive to conventional radiotherapy and chemotherapy.
CONCLUSION: Operative resection with wide resection margins offers the best long-term prognosis. Inadequate resection margins, large tumour size, dedifferentiation, and greater cephalad chordoma extension are associated with poor oncological outcomes. Routine long-term follow-up is essential to enable early detection and treatment of recurrent disease.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chordoma; Metastasis; Prognostic factors; Recurrence; Surgical management; Survival

Mesh:

Year:  2014        PMID: 24793103     DOI: 10.1016/j.ejso.2014.04.008

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  31 in total

1.  Letter to the Editor concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917.

Authors:  Ming-Xiang Zou; Guo-Hua Lv; Xiao-Bin Wang; Jing Li
Journal:  Eur Spine J       Date:  2016-10-18       Impact factor: 3.134

2.  Answer to the Letter to the Editor of J. Li et al. concerning "Surgical treatment of sacral chordoma: survival and prognostic factors" by C. Ruosi et al. (Eur Spine J; 2015; 24(Suppl 7):S912-S917).

Authors:  C Ruosi; G Colella; S L Di Donato; F Granata; M G Di Salvatore; F Fazioli
Journal:  Eur Spine J       Date:  2016-10-20       Impact factor: 3.134

3.  Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.

Authors:  Kai Zhang; Hao Chen; Bin Zhang; Jiajia Sun; Jian Lu; Kangwu Chen; Huilin Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 4.  Immunotherapy as a Potential Treatment for Chordoma: a Review.

Authors:  Shalin S Patel; Joseph H Schwab
Journal:  Curr Oncol Rep       Date:  2016-09       Impact factor: 5.075

5.  Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival.

Authors:  Péter Pál Varga; Zsolt Szövérfi; Charles G Fisher; Stefano Boriani; Ziya L Gokaslan; Mark B Dekutoski; Dean Chou; Nasir A Quraishi; Jeremy J Reynolds; Alessandro Luzzati; Richard Williams; Michael G Fehlings; Niccole M Germscheid; Aron Lazary; Laurence D Rhines
Journal:  Eur Spine J       Date:  2014-12-23       Impact factor: 3.134

6.  Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.

Authors:  Yongkun Yang; Xiaohui Niu; Yuan Li; Weifeng Liu; Hairong Xu
Journal:  Eur Spine J       Date:  2016-12-09       Impact factor: 3.134

7.  What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?

Authors:  Tao Ji; Wei Guo; Rongli Yang; Xiaodong Tang; Yifei Wang; Lin Huang
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

8.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

9.  Prevalence of neuropathic pain after radical sacral chordoma resection: an observational cohort study with 10-year follow-up.

Authors:  Rapin Phimolsarnti; Saranatra Waikakul
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-09-09

10.  Surgical treatment of sacral chordoma: survival and prognostic factors.

Authors:  C Ruosi; G Colella; S L Di Donato; F Granata; M G Di Salvatore; F Fazioli
Journal:  Eur Spine J       Date:  2015-10-12       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.